Opus Point Partners Management’s Pacira BioSciences PCRX Stock Holding History

Opus Point Partners Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,250	Closed	-$489K	–	62
2019 Q2	$489K	Hold	11,250	–	–	0.72%	35
2019 Q1	$428K	Hold	11,250	–	–	0.58%	43
2018 Q4	$484K	Hold	11,250	–	–	1.07%	18
2018 Q3	$553K	Sell	11,250 -1,250	-10%	-$54K	1.32%	24
2018 Q2	$401K	Hold	12,500	–	–	0.87%	30
2018 Q1	$389K	Sell	12,500 -12,500	-50%	-$445K	0.76%	31
2017 Q4	$1.14M	Hold	25,000	–	–	0.99%	32
2017 Q3	$939K	Hold	25,000	–	–	0.84%	35
2017 Q2	$1.19M	Sell	25,000 -25,000	-50%	-$1.16M	1.09%	33
2017 Q1	$2.28M	Hold	50,000	–	–	1.69%	27
2016 Q4	$1.61M	Hold	50,000	–	–	1.29%	28
2016 Q3	$1.71M	Buy	+50,000	New	+$1.96M	0.96%	29
2016 Q2	–	Sell	-35,110	Closed	-$1.86M	–	51
2016 Q1	$1.86M	Buy	35,110 +16,000	+84%	+$936K	1.44%	26
2015 Q4	$1.47M	Sell	19,110 -1,890	-9%	-$107K	0.97%	30
2015 Q3	$863K	Sell	21,000 -26,000	-55%	-$1.59M	0.48%	33
2015 Q2	$3.32M	Buy	47,000 +12,051	+34%	+$949K	2.63%	22
2015 Q1	$3.1M	Buy	+34,949	New	+$3.55M	2.6%	20

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opus Point Partners Management's PCRX Position: Q3 2019 in Review

Opus Point Partners Management sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 11,250 shares — an estimated $489K sold.

Opus Point Partners Management first reported a position in PCRX in Q1 2015 and held it in 17 quarters. The position peaked at $3.32M in Q2 2015. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Opus Point Partners Management reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Opus Point Partners Management sold 11,250 Pacira BioSciences shares in Q3 2019, an estimated $489K.
Opus Point Partners Management first reported a position in Pacira BioSciences in Q1 2015 and held it in 17 quarters.
Opus Point Partners Management's Pacira BioSciences position peaked at $3.32M in Q2 2015.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.